Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 19.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 18,953 shares of the life sciences company’s stock after selling 4,448 shares during the quarter. Sei Investments Co.’s holdings in Integra LifeSciences were worth $430,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of IART. Nisa Investment Advisors LLC grew its position in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after purchasing an additional 2,800 shares in the last quarter. Empowered Funds LLC bought a new position in Integra LifeSciences in the 4th quarter valued at $180,000. Centiva Capital LP acquired a new stake in shares of Integra LifeSciences during the third quarter worth $192,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in shares of Integra LifeSciences during the fourth quarter worth $204,000. Finally, Romano Brothers AND Company acquired a new stake in Integra LifeSciences in the 4th quarter valued at $204,000. Institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Price Performance

Shares of IART opened at $19.19 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm’s 50 day moving average price is $22.63 and its 200 day moving average price is $22.31. The firm has a market cap of $1.48 billion, a PE ratio of -213.20, a PEG ratio of 0.73 and a beta of 1.24. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $34.41.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter in the prior year, the company earned $0.89 EPS. The company’s revenue was up 11.5% on a year-over-year basis. As a group, research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.